Roche Media NewsThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2

91 records returned

European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting the initial assessment of medicinal products that have been filed for marketing authorisation in Europe, has issued a negative opinion relating to the approval of Avastin (bevacizumab) alone or in combination with irinotecan chemotherapy for the treatment of relapsed or progressive glioblastoma (GBM), the most aggressive type of primary malignant brain cancer. (Source: Roche Media News)
Source: Roche Media News - November 20, 2009 Category: Pharmaceuticals Source Type: organizations

ACTEMRA inhibits progression of joint destruction in RA patients by over 80% compared to methotrexate aloneEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Two-year data from the LITHE study, being presented at the American College of Rheumatology, show that, with long-term use, patients with rheumatoid arthritis treated with ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) plus methotrexate (MTX) suffered 81% less damage to their joints compared to those treated with MTX, the current standard therapy, alone1. For patients, this means that their joint damage is significantly reduced, and that they can therefore continue to enjoy their lives without the evolving disability usually associated with the disease. (Source: Roche Media News)
Source: Roche Media News - October 17, 2009 Category: Pharmaceuticals Source Type: organizations

Roche reports further accelerated sales growth in third quarterEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Group sales up 3.1 billion to 36.4 billion Swiss francs in first nine months, an increase of 11% in local currencies (9% in Swiss francs); both divisions grow significantly faster than their respective markets ; Genentech integration progressing successfully; New Group leadership appointed (Source: Roche Media News)
Source: Roche Media News - October 15, 2009 Category: Pharmaceuticals Source Type: organizations

Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A detailed analysis of the Phase III ToGA study announced today revealed an unprecedented survival benefit for patients whose tumours exhibited a particularly high level of HER2 when Herceptin (trastuzumab) was added to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin). (Source: Roche Media News)
Source: Roche Media News - September 24, 2009 Category: Pharmaceuticals Source Type: organizations

Continuous improvements in animal welfare within Roche ResearchEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced the winners of its global 3Rs Award Program - a unique and innovative program that helps to reduce and limit the use of animals in preclinical research - to recognise and reward innovation and continuous improvement in animal welfare within the Roche research organisation. (Source: Roche Media News)
Source: Roche Media News - September 24, 2009 Category: Pharmaceuticals Source Type: organizations

From inoperable disease to potentially life saving surgery - new Avastin data gives hope to colorectal cancer patients with liver metastasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New data from several studies presented at ECCO 15 and ESMO 34 confirm unique benefits of Avastin (bevacizumab) and Xeloda (capecitabine) in treatment of colon cancer: Combination of Avastin with standard chemotherapy resulted in shrinkage or disappearance of liver metastases in 78% of patients with advanced colon cancer. A third of patients (Source: Roche Media News)
Source: Roche Media News - September 23, 2009 Category: Pharmaceuticals Source Type: organizations

Roche announces results from two early studies which show promise for patients with malignant melanomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New data from phase II Avastin study and a phase I extension study of highly selective BRAF inhibitor (Source: Roche Media News)
Source: Roche Media News - September 23, 2009 Category: Pharmaceuticals Source Type: organizations

Avastin could play an important role in improving the daily lives of patients with the most aggressive form of brain cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Analysis of BRAIN study shows that patients may have a stabilisation or improvement in neurocognitive function and a reduction in steroid use. (Source: Roche Media News)
Source: Roche Media News - September 22, 2009 Category: Pharmaceuticals Source Type: organizations

Two new studies report increased survival rates in Tamiflu-treated patients with avian flu (H5N1) and severe seasonal fluEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
53% of patients with H5N1 infection survived when treated with Tamiflu compared with 12% of untreated patients. Rate of death was reduced by 37% in high-risk patients with severe seasonal flu compared with no treatment (Source: Roche Media News)
Source: Roche Media News - September 13, 2009 Category: Pharmaceuticals Source Type: organizations

Roche announces new Corporate Executive CommitteeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
William M. Burns, Juergen Schwiezer and Jonathan Knowles to retire – Pascal Soriot appointed COO Pharma Division and Daniel O’Day appointed COO Diagnostics Division – Jean-Jacques Garaud and Dan Zabrowski to become Members of Enlarged Executive Committee – Ian Clark appointed CEO Genentech (Source: Roche Media News)
Source: Roche Media News - September 8, 2009 Category: Pharmaceuticals Source Type: organizations

Roche recognised as new Super Sector Leader in Dow Jones Sustainability IndexEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche has been rated as the new Super Sector Leader in Healthcare on the Dow Jones Sustainability Index, placing Roche as the most sustainable healthcare company worldwide. Selection into the global Dow Jones Sustainability World Index as well as the pan-European Dow Jones STOXX Sustainability Index follows a thorough analysis of corporate economic, environmental and social performance, and takes into account elements such as corporate governance, risk management, access to medicines, climate change, supply chain standards, stakeholder engagement and labor practice. (Source: Roche Media News)
Source: Roche Media News - September 3, 2009 Category: Pharmaceuticals Source Type: organizations

MabThera approved in Europe for use in patients with previously-treated chronic lymphocytic leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that the European Commission has approved MabThera (rituximab) for use in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the most common form of the disease in adults. The approval is supported by the impressive results from REACH, the largest randomised clinical trial ever reported in previously-treated CLL. (Source: Roche Media News)
Source: Roche Media News - September 3, 2009 Category: Pharmaceuticals Source Type: organizations

Avastin approved in US for the most common type of kidney cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab) plus interferon alpha for people with metastatic renal cell carcinoma, the most common type of kidney cancer. (Source: Roche Media News)
Source: Roche Media News - August 3, 2009 Category: Pharmaceuticals Source Type: organizations

Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein OcclusionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that the Phase III study CRUISE showed Lucentis (ranibizumab injection) improved vision in patients with swelling in the retina (macular edema) due to central retinal vein occlusion (RVO). (Source: Roche Media News)
Source: Roche Media News - July 30, 2009 Category: Pharmaceuticals Source Type: organizations

European commission approves broader label for Avastin allowing combination with docetaxel for the first-line treatment of advanced (metastatic) breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Physicians will be able to offer more patients Avastin-based treatment options (Source: Roche Media News)
Source: Roche Media News - July 29, 2009 Category: Pharmaceuticals Source Type: organizations

MabThera receives positive opinion in Europe for treating patients whose chronic lymphocytic leukaemia returnsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that the European Union’s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation for the use of MabThera (rituximab) in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL). (Source: Roche Media News)
Source: Roche Media News - July 24, 2009 Category: Pharmaceuticals Source Type: organizations

Double-digit increase in sales, operating profit and Core EPSEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Integration of Genentech progressing rapidly; full-year outlook raised; Group sales up 2 billion to 24 billion Swiss francs, an increase of 10% in local currencies (9% in Swiss francs); both divisions grow significantly faster than their respective markets. (Source: Roche Media News)
Source: Roche Media News - July 23, 2009 Category: Pharmaceuticals Source Type: organizations

Xeloda in combination with oxaliplatin shown to be effective in early colon cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today results from the international phase III study NO16968 (XELOXA), investigating oral Xeloda in combination with intravenous oxaliplatin (XELOX) immediately after surgery, which show that patients with colon cancer taking XELOX live disease free for longer compared to those taking the commonly used intravenous chemotherapy combination 5-fluorouracil/leucovorin (5-FU/LV). (Source: Roche Media News)
Source: Roche Media News - July 20, 2009 Category: Pharmaceuticals Source Type: organizations

New data from phase III SATURN study shows Tarceva improves overall survival when used immediately after initial chemotherapy in patients with advanced lung cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that SATURN, a pivotal Phase III study, met a key secondary endpoint of extending overall survival in patients with advanced non-small cell lung cancer (NSCLC) who received Tarceva(erlotinib) immediately after their initial chemotherapy. (Source: Roche Media News)
Source: Roche Media News - July 13, 2009 Category: Pharmaceuticals Source Type: organizations

Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein OcclusionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion. (Source: Roche Media News)
Source: Roche Media News - July 2, 2009 Category: Pharmaceuticals Source Type: organizations

New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
RA patients with enhanced response identified (Source: Roche Media News)
Source: Roche Media News - June 11, 2009 Category: Pharmaceuticals Source Type: organizations

New data reinforces long-term efficacy of ACTEMRA in rheumatoid arthritis across all patient population typesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Up to 56% of patients with active rheumatoid arthritis (RA) treated with ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) for over two years, will achieve disease remission, according to new data presented today at the European League Against Rheumatism (EULAR) congress. (Source: Roche Media News)
Source: Roche Media News - June 9, 2009 Category: Pharmaceuticals Source Type: organizations

Roche to commence phase III trials with innovative treatment designed to lower cardiovascular risk in diabetes patients with recent heart attackEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce cardiovascular morbidity and mortality in high risk patients with type 2 diabetes. (Source: Roche Media News)
Source: Roche Media News - June 9, 2009 Category: Pharmaceuticals Source Type: organizations

Encouraging first data on new targeted treatment for patients with melanoma - the deadliest form of skin cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today results from a phase I study with PLX4032 (R7204) a new, highly selective and promising treatment for patients with advanced melanoma whose cancer harbours the BRAF mutation (known as mutation-positive). (Source: Roche Media News)
Source: Roche Media News - June 1, 2009 Category: Pharmaceuticals Source Type: organizations

Herceptin landmark study (ToGA) reveals unprecedented survival benefit in HER2-positive stomach cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Data from the ToGA study presented today at the American Society for Clinical Oncology Annual Meeting in Orlando, Florida showed that adding Herceptin (trastuzumab) to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin) prolongs the lives of patients with this aggressive cancer on average by nearly three months to 13.8 months. (Source: Roche Media News)
Source: Roche Media News - May 31, 2009 Category: Pharmaceuticals Source Type: organizations

Maintenance treatment with Avastin and Tarceva in combination helps lung cancer patients live longer without their disease worseningEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Phase III ATLAS study achieves a new milestone in treating advanced lung cancer (Source: Roche Media News)
Source: Roche Media News - May 30, 2009 Category: Pharmaceuticals Source Type: organizations

Full results from first Phase III study of Avastin in adjuvant colon cancer announcedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Results suggest future trials may hold promise for Avastin as early-stage colon cancer treatment even though C-08 study does not meet primary endpoint (Source: Roche Media News)
Source: Roche Media News - May 30, 2009 Category: Pharmaceuticals Source Type: organizations

Two-year data reinforce effectiveness of ACTEMRA in inhibiting joint damage and improving physical function in patients with rheumatoid arthritisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that new two-year data from the LITHE study demonstrate that ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) continues to be highly effective at inhibiting joint structural damage and maintaining consistently high remission rates. (Source: Roche Media News)
Source: Roche Media News - May 25, 2009 Category: Pharmaceuticals Source Type: organizations

Roche to present major advances with targeted cancer medicines at ASCOEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
More than 500 scientific abstracts to be presented across 20 types of cancers. Results could significantly improve the way cancer is treated for patients with inoperable stomach cancer; advanced melanoma; lung and breast cancers. (Source: Roche Media News)
Source: Roche Media News - May 14, 2009 Category: Pharmaceuticals Source Type: organizations

Roche provides additional donation of 5.65 million packs of Tamiflu to World Health OrganizationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today announced a new donation to the World Health Organization (WHO) of 5.65 million courses of treatment of the antiviral drug Tamiflu (oseltamivir). (Source: Roche Media News)
Source: Roche Media News - May 12, 2009 Category: Pharmaceuticals Source Type: organizations

Roche rapidly responds to WHO request to deploy Rapid Response Stockpiles of Tamiflu to tackle global emergence of a new H1N1 influenza A strain - swine fluEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today confirms that the World Health Organisation (WHO) has requested deployment of the “Rapid Response Stockpile.” The stockpile is being deployed to countries in need at the discretion of WHO. (Source: Roche Media News)
Source: Roche Media News - May 2, 2009 Category: Pharmaceuticals Source Type: organizations

Roche responds to WHO move to influenza pandemic alert phase 5Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche tonight confirms that it has been in contact with the World Health Organization (WHO) following the announcement to move to influenza pandemic alert phase 5. (Source: Roche Media News)
Source: Roche Media News - April 29, 2009 Category: Pharmaceuticals Source Type: organizations

Roche steps up preparedness level in response to WHO's increase to pandemic alert phase 4Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today confirms that it is working closely with the World Health Organization (WHO) and Governments around the world to make the oral antiviral medication Tamiflu available to patients in need following the increased reports of outbreaks of swine flu. The WHO and US CDC report Tamiflu is active against this new swine flu virus A(H1N1). (Source: Roche Media News)
Source: Roche Media News - April 29, 2009 Category: Pharmaceuticals Source Type: organizations

Phase III C-08 study of Avastin in early-stage colon cancer does not meet primary endpointEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today announced the results of the first phase III trial evaluating the use of Avastin (bevacizumab) plus chemotherapy (FOLFOX) for the treatment of colon cancer immediately following surgery (adjuvant therapy) compared to chemotherapy alone. (Source: Roche Media News)
Source: Roche Media News - April 22, 2009 Category: Pharmaceuticals Source Type: organizations

Roche strongly outperforms market in first quarterEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Group sales up 8% in local currencies and 7% in Swiss francs to 11.6 billion Swiss francs (-1% in US dollars); Roche completes transaction to take full ownership of Genentech - key decisions on organisational structure and management appointments taken; Full-year outlook to be updated to include impact of Genentech transaction and communicated with half-year results (Source: Roche Media News)
Source: Roche Media News - April 16, 2009 Category: Pharmaceuticals Source Type: organizations

Roche Diabetes Care supports "Changing Diabetes in Children"Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today announced that it will join forces with Novo Nordisk and the World Diabetes Foundation (WDF) in Novo Nordisk’s five-year program called “Changing Diabetes in Children”. Roche Diabetes Care will actively endorse humanitarian activities in this project which is starting in Tanzania, Uganda, Cameroon, Guinea-Conakry and the Democratic Republic of Congo. (Source: Roche Media News)
Source: Roche Media News - April 15, 2009 Category: Pharmaceuticals Source Type: organizations

Roche and Genentech announce organizational and leadership decisionsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Following the completion of the Genentech transaction Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) today announced the successful start of the integration. Building on the long-standing and trustful relationship of the two companies, senior leaders from Genentech and Roche have made considerable progress in a short period of time to set the course for the integration. (Source: Roche Media News)
Source: Roche Media News - April 14, 2009 Category: Pharmaceuticals Source Type: organizations

Roche to introduce new LightCycler MRSA Advanced Test in the EUEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that its new LightCycler test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) is now available with the CE Mark, allowing it to be sold for clinical use in the European Union. (Source: Roche Media News)
Source: Roche Media News - April 2, 2009 Category: Pharmaceuticals Source Type: organizations

Roche completes acquisition of GenentechEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech (NYSE: DNA) announced today that Roche has completed its acquisition of Genentech pursuant to a short-form merger in which Genentech became a wholly-owned member of the Roche Group. (Source: Roche Media News)
Source: Roche Media News - March 26, 2009 Category: Pharmaceuticals Source Type: organizations

Roche completes tender offer for GenentechEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) announced today that its wholly-owned subsidiary, Roche Investments USA Inc., completed its tender offer for the publicly held shares of Genentech (NYSE: DNA). The offer expired at midnight, New York City time, at the end of Wednesday, March 25. (Source: Roche Media News)
Source: Roche Media News - March 26, 2009 Category: Pharmaceuticals Source Type: organizations

Herceptin now shown to significantly prolong the lives of patients with HER2-positive advanced stomach cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today announced results from a major international study which show that adding Herceptin (trastuzumab) to standard chemotherapy significantly prolongs lives of patients with HER2-positive stomach (gastric) cancer. (Source: Roche Media News)
Source: Roche Media News - March 18, 2009 Category: Pharmaceuticals Source Type: organizations

Roche acquires innovatis AG to complement its product portfolio in the rapidly growing area of cellular analyticsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today announced that it has signed a definite agreement under which Roche will acquire 100% of innovatis, a privately held company based in Bielefeld, Germany. (Source: Roche Media News)
Source: Roche Media News - March 16, 2009 Category: Pharmaceuticals Source Type: organizations

Roche and Genentech reach a friendly agreement to combine the two organizations and create a leader in healthcare innovationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche (SWX: ROG.VX; RO.S) and Genentech (NYSE: DNA) announced today that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US$95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. (Source: Roche Media News)
Source: Roche Media News - March 12, 2009 Category: Pharmaceuticals Source Type: organizations

Herceptin proven to benefit women with HER2 positive early breast cancer - latest results from the HERA studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Breast International Group (BIG) in collaboration with Roche announced today that women with HER2 positive early breast cancer continue to benefit from Herceptin (trastuzumab) several years after treatment completion and as a result enjoy a longer life disease free. The patients were treated for one year with Herceptin and followed up for four years. These data from the HERA study were presented at the Primary Therapy in Early Breast Cancer conference in St. Gallen, Switzerland. (Source: Roche Media News)
Source: Roche Media News - March 11, 2009 Category: Pharmaceuticals Source Type: organizations

Roche Annual General Meeting: dividend raised by 9 percentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche's Annual General Meeting, which was held today in Basel, has approved all the Board of Directors' proposals. The 703 shareholders in attendance, representing 144,334,099, or 90.2% of a total of 160,000,000 bearer shares, approved the 2008 Annual Report and financial statements. (Source: Roche Media News)
Source: Roche Media News - March 10, 2009 Category: Pharmaceuticals Source Type: organizations

Roche increases offer price for Genentech shares to US$ 93 per share and extends offerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche (SWX: ROG.VX; RO.S) announced today that it has increased its offer price for all outstanding publicly-held shares of Genentech (NYSE: DNA) to US$ 93 per share and extended the offer to 12:00 midnight, New York City time, on Friday, March 20, 2009. All other terms and conditions of the tender offer remain unchanged. (Source: Roche Media News)
Source: Roche Media News - March 6, 2009 Category: Pharmaceuticals Source Type: organizations

MabThera approved in the EU for patients with chronic lymphocytic leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that the European Commission has approved MabThera (rituximab) in combination with chemotherapy for use in patients with previously-untreated chronic lymphocytic leukaemia (CLL), the most common type of leukaemia to affect adults. (Source: Roche Media News)
Source: Roche Media News - February 27, 2009 Category: Pharmaceuticals Source Type: organizations

For the first time, doctors can predict which hepatitis B patients have the highest chance to achieve treatment success with PegasysEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New data presented today showed that, for the first time, doctors can predict which hepatitis B patients treated with Pegasys (peginterferon alfa-2a) have the highest chance to achieve a positive treatment outcome - and even a clinical cure. The study results represent an important step forward, as some patients will now be able to feel confident during their Pegasys treatment about the likelihood of beating the disease. (Source: Roche Media News)
Source: Roche Media News - February 16, 2009 Category: Pharmaceuticals Source Type: organizations